# Arcturus Therapeutics

Type: Company (ARCT)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/arcturus-therapeutics
Canonical HTML page: https://getbiobrief.com/entity/arcturus-therapeutics

## Recent coverage (2 stories)

### Analyst Sentiment Diverges for Biotech Leaders Apogee and Arcturus
2026-03-19 14:56:50 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Apogee Therapeutics and Arcturus Therapeutics experienced a wave of conflicting analyst activity on Thursday, with both companies facing significant downgrades alongside new initiations. This institutional tug-of-war highlights the increasing volatility and selective nature of investment in mid-cap biotechnology firms.
Full story: https://getbiobrief.com/story/apogee-arcturus-analyst-ratings-divergence

### Arcturus and Rigel Q4 Previews: mRNA Innovation vs. Oncology Commercialization
2026-03-02 22:54:15 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Arcturus Therapeutics and Rigel Pharmaceuticals are set to report Q4 2025 results, highlighting a pivotal year for mRNA platform validation and oncology market expansion. Investors are focused on Arcturus's sa-mRNA commercial progress in Japan and Rigel's sales trajectory for its flagship hematology treatments.
Full story: https://getbiobrief.com/story/arcturus-rigel-q4-2025-earnings-preview

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.